14 results
Summary of Non-Insulin Agents Used to Treat Diabetes

#Diabetes #Pharmacology #Comparison #Table #Medications #Noninsulin #Orals #Agents
Summary of Non-Insulin ... Used to Treat Diabetes ... #Diabetes #Pharmacology ... #Comparison #Table ... Medications #Noninsulin #Orals
Profiles of Antidiabetic Medications - AACE 2018 

#Antidiabetic #Medications #Profiles #SideEffects #Table #DecisionAid #Orals #DM2 #Diabetes
#SideEffects #Table ... #DecisionAid #Orals ... #DM2 #Diabetes ... #Endocrinology # ... Pharmacology #Management
Diabetes Medications Summary Table
Insulin
Lifestyle modifications
Metformin
Sulfonylureas
GLP-1 receptor agonists - ↓ major adverse CV events
TZDs
DPP-4 inhibitors
SGLT2 inhibitors -
Diabetes Medications ... Summary Table ... GLP-1 receptor agonists ... #medications #table ... comparison #management #endocrinology
DPP-4 Inhibitors - Pharmacology Summary
Mechanisms of Action: Inhibits DPP-4 (dipeptidyl peptidase 4), which normally inactivates GLP-1
4 Inhibitors - Pharmacology ... Summary Mechanisms ... GLP-I receptor agonist ... #Summary #DM2 # ... diabetes #endocrinology
GLP-1 Receptor Agonists - Pharmacology Summary
Mechanisms of Action: Stimulate glucose-dependent insulin release from the pancreas (GLP-1
- Pharmacology ... Summary Mechanisms ... Ozempic), or daily tablet ... Summary #DM2 #diabetes ... #endocrinology
GLP-1 Agonists

Adlyxin (Lixisenatide) Daily
Bydureon (Exenatide ER) Weekly 
Ozempic (Semaglutide) Weekly 
Trulicity (Dulaglutide) Weekly 
Victoza (Liraglutide) Daily
They work primarily ... There is an ORAL ... #Pharmacology #Dosing ... #Diabetes #DM2 ... #Endocrinology
Antiplatelet Medications - Summary Table

Aspirin - Inhibits cyclooxygenase, preventing formation of thromboxane A2
 • Acute coronary
Medications - Summary ... Table Aspirin ... Acute stroke • Primary ... #Medications #Summary ... #Table #Pharmacology
Diabetes Mellitus Type 2 Inpatient Medication Guide

Classes: Biguanide, Sulfonylurea, TZD, DPP-4 inhibitor, GLP-1 receptor agonist, SGLT2i,
Diabetes Mellitus ... GLP-1 receptor agonist ... #Medications #pharmacology ... #comparison #table ... #endocrinology
Rybelsus (oral semaglutide) - First Oral GLP-1 Agonist
Dosing:
3 mg daily x 30 days, then 7 mg
-1 Agonist Dosing ... drug to remain stable ... #semaglutide #Diabetes ... #Pharmacology # ... Endocrinology
Metformin Pharmacology Summary
Mechanisms of Action:
 • Suppresses gluconeogenesis by the liver
 • Increases insulin-mediated glucose utilization
Metformin Pharmacology ... Summary Mechanisms ... Most effective oral ... #Summary #DM2 # ... diabetes #endocrinology